Feature

Sen. Schumer backs federal decriminalization of marijuana


 

U.S. Sen. Chuck Schumer, the Senate majority leader, is cosponsoring legislation that would decriminalize marijuana at the federal level.

Marijuana leaves VladK213/Getty Images

The Cannabis Administration & Opportunity Act would allow the federal government to regulate and tax marijuana sales for the first time and would stop the federal prosecution of people for possessing and selling the drug, The New York Times reported. States could still make their own marijuana laws, however.

The bill calls for using money raised by taxing marijuana to help poor people and communities of color that have been unduly affected by marijuana laws.

Arrests and convictions for nonviolent marijuana offenses would be automatically expunged, The New York Times reported.

“The War on Drugs has been a war on people – particularly people of color,” a draft of the bill said, adding that the bill “aims to end the decades of harm inflicted on communities of color by removing cannabis from the federal list of controlled substances and empowering states to implement their own cannabis laws.”

But passage of the bill is highly uncertain because of strong Republican opposition in the Senate, where Democrats hold a narrow majority, according to The New York Times.

President Biden has not said he supports such legislation.

Sen. Schumer signaled his intentions when he spoke on April 20, the unofficial holiday for marijuana smokers.

“Hopefully, the next time this unofficial holiday of 4/20 rolls around, our country will have made progress in addressing the massive overcriminalization of marijuana in a meaningful and comprehensive way,” he said at the time, the newspaper reported.

Cosponsors were U.S. Sen. Cory Booker of New Jersey and U.S. Sen. Ron Wyden of Oregon, chairman of the Senate Finance Committee.

A version of this article first appeared on WebMD.com.

Recommended Reading

Joint pain in patients with hemophilia may be neuropathic
MDedge Rheumatology
FDA warning letters target OTC cannabidiol product claims for pain relief
MDedge Rheumatology
Doctors more likely to prescribe opioids to COVID ‘long-haulers,’ raising addiction fears
MDedge Rheumatology
FDA OKs higher-dose naloxone nasal spray for opioid overdose
MDedge Rheumatology
High variability found in studies assessing hemophilia-related pain
MDedge Rheumatology
Hypertension worsened by commonly used prescription meds
MDedge Rheumatology
NSAIDs don’t make COVID-19 worse in hospitalized patients
MDedge Rheumatology
Which comes first in osteoarthritis: The damage or the pain?
MDedge Rheumatology
Physician convicted in buprenorphine scheme faces up to 20 years in prison
MDedge Rheumatology
‘Long haul’ COVID recovery worse than cancer rehab for some: CDC
MDedge Rheumatology